Clovis Sets Brisk Development Timetable For Lung Cancer Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The oncology drug developer expects to file its third generation EGFR inhibitor for the treatment of NSCLC by the end of 2015, CEO Patrick Mahaffy told investors during an R&D day Jan. 27. Investors are enthusiastic about the potential of the drug, which could address a sizeable commercial market.
You may also be interested in...
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.
J&J’s Growth Plan Calls For Mega-Blockbusters And A Leading Oncology Franchise
Johnson & Johnson laid out long-term revenue growth guidance and plans for its Innovative Medicines pipeline during an R&D day.
EyePoint Hits New Durability Milestone For Wet AMD Treatment
Positive Phase II data in wet AMD showing potential for dosing out to six months could spur partnering interest ahead of Phase III development.